Compass Therapeutics (NASDAQ:CMPX) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a sell rating to a strong sell rating in a research note issued to investors on Saturday.

A number of other brokerages have also recently issued reports on CMPX. D. Boral Capital restated a “buy” rating and set a $30.00 target price on shares of Compass Therapeutics in a research report on Monday, April 27th. Raymond James Financial lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 28th. Canaccord Genuity Group dropped their price objective on shares of Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, April 28th. Piper Sandler lifted their price objective on Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, LADENBURG THALM/SH SH initiated coverage on Compass Therapeutics in a research note on Wednesday, July 1st. They issued a “buy” rating and a $5.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.77.

Compass Therapeutics Stock Up 3.3%

Shares of CMPX stock opened at $2.22 on Friday. The stock has a market cap of $399.80 million, a P/E ratio of -5.55 and a beta of 0.92. Compass Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $6.88. The business has a fifty day simple moving average of $2.09 and a 200-day simple moving average of $3.83.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, sell-side analysts anticipate that Compass Therapeutics will post -0.43 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds have recently modified their holdings of the company. Parallel Advisors LLC purchased a new position in shares of Compass Therapeutics during the first quarter valued at approximately $28,000. Flagship Harbor Advisors LLC acquired a new stake in Compass Therapeutics during the fourth quarter worth approximately $32,000. Russell Investments Group Ltd. grew its stake in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after acquiring an additional 7,592 shares during the period. Xponance LLC purchased a new stake in Compass Therapeutics in the 4th quarter worth approximately $55,000. Finally, CIBC Bancorp USA Inc. acquired a new position in Compass Therapeutics in the 3rd quarter valued at $37,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.